# A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1

> **NCT00790673** · PHASE1,PHASE2 · COMPLETED · sponsor: **Can-Fite BioPharma** · enrollment: 32 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** CF 102
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00790673
- **Lead sponsor:** Can-Fite BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2011-06
- **Final completion:** 2011-07
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2015-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00790673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00790673, "A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00790673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*